Skip to main content
Top
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

RETRACTED ARTICLE: Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma

Authors: Xiuru Ma, Xiaoming Li, Xiuying Lu, Lifeng Jia, Hui Li, Qi Song

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Although the expression of tumor necrosis factor receptors (TNFRs) has been associated with clinicopathologic features of some other cancers, their roles in hypopharyngeal squamous cell carcinoma (HPSCC) have not been documented. Forty-five HPSCC specimens were analyzed for the expression of TNFR1 and TNFR2 and its relationship with clinicopathologic factors. Interaction between the two receptors and its effects on TNF-α was investigated by neutralizing TNFR1 and upregulation of TNFR2. The results indicated that, in HPSCC specimens, the expression of TNFR1 but not TNFR2 is associated with clinical staging, T stage, cervical lymph node metastasis, and histologic grade in HPSCC. In Fadu cells, when conjugating with its receptors, TNF-α mediates proliferation effects, and neutralizing TNFR1 and/or upregulating TNFR2 evokes proliferation-inhibiting and apoptosis-inducing effects and potentiates cisplatin (DDP)-induced growth inhibition and apoptosis induction. In conclusion, interaction of TNFR1 with TNFR2 determines the biological characters of HPSCC, and TNFR1 may dominate this process. Moreover, interaction between the two receptors plays important roles in determining the fates of HPSCC cells and thus may serve as a therapeutic target for developing new therapeutic strategies for HPSCC.
Literature
1.
go back to reference Dou YL, Lin JP, Liu FE, Wang LY, Shu HH, Jiang N, et al. Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300 expression. Tumor Biol. 2014;35(8):7499–504.CrossRef Dou YL, Lin JP, Liu FE, Wang LY, Shu HH, Jiang N, et al. Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300 expression. Tumor Biol. 2014;35(8):7499–504.CrossRef
2.
go back to reference Nishimura H, Sasaki R, Yoshida K, Miyawaki D, Okamoto Y, Kiyota N, et al. Radiotherapy for Stage I or II hypopharyngeal carcinoma. J Radiat Res. 2012;53(6):892–9.CrossRefPubMedPubMedCentral Nishimura H, Sasaki R, Yoshida K, Miyawaki D, Okamoto Y, Kiyota N, et al. Radiotherapy for Stage I or II hypopharyngeal carcinoma. J Radiat Res. 2012;53(6):892–9.CrossRefPubMedPubMedCentral
3.
go back to reference Yu Y, Wang XL, Xu ZG, Fan CC, Li Q. Prognostic value of lymph node ratio in hypopharyngeal squamous cell carcinoma after chemoradiotherapy. Chin Med J (Engl). 2013;126(21):4139–44. Yu Y, Wang XL, Xu ZG, Fan CC, Li Q. Prognostic value of lymph node ratio in hypopharyngeal squamous cell carcinoma after chemoradiotherapy. Chin Med J (Engl). 2013;126(21):4139–44.
4.
go back to reference Chu PY, Chang SY. Reconstruction of the hypopharynx after surgical treatment of squamous cell carcinoma. J Chin Med Assoc. 2009;72(7):351–5.CrossRefPubMed Chu PY, Chang SY. Reconstruction of the hypopharynx after surgical treatment of squamous cell carcinoma. J Chin Med Assoc. 2009;72(7):351–5.CrossRefPubMed
5.
go back to reference Krstevska V, Stojkovski I, Zafirova-Ivanovska B, Crvenkova S. Prognostic factors in patients with advanced hypopharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy. J BUON. 2012;17(2):327–36.PubMed Krstevska V, Stojkovski I, Zafirova-Ivanovska B, Crvenkova S. Prognostic factors in patients with advanced hypopharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy. J BUON. 2012;17(2):327–36.PubMed
6.
go back to reference Zhu G, Cai G, Liu Y, Tan H, Yu C, Huang M, et al. Quantitative iTRAQ LC-MS/MS proteomics reveals transcription factor crosstalk and regulatory networks in hypopharyngeal squamous cell carcinoma. J Cancer. 2014;5(7):525–36.CrossRefPubMedPubMedCentral Zhu G, Cai G, Liu Y, Tan H, Yu C, Huang M, et al. Quantitative iTRAQ LC-MS/MS proteomics reveals transcription factor crosstalk and regulatory networks in hypopharyngeal squamous cell carcinoma. J Cancer. 2014;5(7):525–36.CrossRefPubMedPubMedCentral
7.
go back to reference Wilson DD, Rahimi AS, Saylor DK, Stelow EB, Jameson MJ, Shonka DC, et al. p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138(6):556–61.CrossRefPubMed Wilson DD, Rahimi AS, Saylor DK, Stelow EB, Jameson MJ, Shonka DC, et al. p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138(6):556–61.CrossRefPubMed
9.
go back to reference Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305–8.CrossRefPubMed Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305–8.CrossRefPubMed
10.
go back to reference Ardestani S, Li B, Deskins DL, Wu H, Massion PP, Young PP. Membrane versus soluble isoforms of TNF-alpha exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res. 2013;73(13):3938–50.CrossRefPubMedPubMedCentral Ardestani S, Li B, Deskins DL, Wu H, Massion PP, Young PP. Membrane versus soluble isoforms of TNF-alpha exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res. 2013;73(13):3938–50.CrossRefPubMedPubMedCentral
11.
go back to reference Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, et al. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia. 2004;6(4):364–73.CrossRefPubMedPubMedCentral Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, et al. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia. 2004;6(4):364–73.CrossRefPubMedPubMedCentral
12.
go back to reference Ziprin P, Ridgway PF, Pfistermuller KL, Peck DH, Darzi AW. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes. 2003;10(2):141–54.CrossRefPubMed Ziprin P, Ridgway PF, Pfistermuller KL, Peck DH, Darzi AW. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes. 2003;10(2):141–54.CrossRefPubMed
13.
go back to reference Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1990;61(2):351–9.CrossRefPubMed Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1990;61(2):351–9.CrossRefPubMed
14.
go back to reference Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem. 2003;278(51):51613–21.CrossRefPubMed Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem. 2003;278(51):51613–21.CrossRefPubMed
15.
go back to reference White LE, Santora RJ, Cui Y, Moore FA, Hassoun HT. TNFR1-dependent pulmonary apoptosis during ischemic acute kidney injury. Am J Physiol Lung Cell Mol Physiol. 2012;303(5):L449–459.CrossRefPubMedPubMedCentral White LE, Santora RJ, Cui Y, Moore FA, Hassoun HT. TNFR1-dependent pulmonary apoptosis during ischemic acute kidney injury. Am J Physiol Lung Cell Mol Physiol. 2012;303(5):L449–459.CrossRefPubMedPubMedCentral
16.
go back to reference Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Ren Physiol. 2003;285(4):F610–618.CrossRef Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Ren Physiol. 2003;285(4):F610–618.CrossRef
17.
go back to reference Park B, Sung B, Yadav VR, Chaturvedi MM, Aggarwal BB. Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway. Biochem Pharmacol. 2011;82(9):1134–44.CrossRefPubMedPubMedCentral Park B, Sung B, Yadav VR, Chaturvedi MM, Aggarwal BB. Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway. Biochem Pharmacol. 2011;82(9):1134–44.CrossRefPubMedPubMedCentral
18.
go back to reference Ruspi G, Schmidt EM, McCann F, Feldmann M, Williams RO, Stoop AA, et al. TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages. Cell Signal. 2014;26(4):683–90.CrossRefPubMed Ruspi G, Schmidt EM, McCann F, Feldmann M, Williams RO, Stoop AA, et al. TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages. Cell Signal. 2014;26(4):683–90.CrossRefPubMed
19.
go back to reference Kondo S, Sauder DN. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-alpha-induced skin inflammation. Eur J Immunol. 1997;27(7):1713–8.CrossRefPubMed Kondo S, Sauder DN. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-alpha-induced skin inflammation. Eur J Immunol. 1997;27(7):1713–8.CrossRefPubMed
20.
go back to reference Dobrzycka B, Terlikowski SJ, Garbowicz M, Niklińska W, Bernaczyk PS, Nikliński J, et al. Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem Cytobiol. 2009;47(4):609–13.PubMed Dobrzycka B, Terlikowski SJ, Garbowicz M, Niklińska W, Bernaczyk PS, Nikliński J, et al. Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem Cytobiol. 2009;47(4):609–13.PubMed
21.
go back to reference Nakayama S, Yokote T, Tsuji M, Akioka T, Miyoshi T, Hirata Y, et al. TNF-alpha receptor 1 expression predicts poor prognosis of diffuse large b-cell lymphoma, not otherwise specified. Am J Surg Pathol. 2014;38(8):1138–46.PubMed Nakayama S, Yokote T, Tsuji M, Akioka T, Miyoshi T, Hirata Y, et al. TNF-alpha receptor 1 expression predicts poor prognosis of diffuse large b-cell lymphoma, not otherwise specified. Am J Surg Pathol. 2014;38(8):1138–46.PubMed
22.
go back to reference Chiechi A, Novello C, Magagnoli G, Petricoin 3rd EF, Deng J, Benassi MS, et al. Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. Clin Cancer Res. 2013;19(9):2473–85.CrossRefPubMedPubMedCentral Chiechi A, Novello C, Magagnoli G, Petricoin 3rd EF, Deng J, Benassi MS, et al. Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. Clin Cancer Res. 2013;19(9):2473–85.CrossRefPubMedPubMedCentral
23.
go back to reference Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 2002;416(6878):345–7.CrossRefPubMed Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 2002;416(6878):345–7.CrossRefPubMed
24.
go back to reference Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene. 2007;26(10):1385–97.CrossRefPubMed Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene. 2007;26(10):1385–97.CrossRefPubMed
25.
go back to reference Isonishi S, Shiotsuka S, Ochiai K, Yasuda M, Terashima Y. Tumor necrosis factor-alpha (TNF alpha) enhances cisplatin cytotoxicity to ovarian carcinoma xenografts. Oncol Rep. 1996;3(6):1049–53.PubMed Isonishi S, Shiotsuka S, Ochiai K, Yasuda M, Terashima Y. Tumor necrosis factor-alpha (TNF alpha) enhances cisplatin cytotoxicity to ovarian carcinoma xenografts. Oncol Rep. 1996;3(6):1049–53.PubMed
26.
go back to reference Benedetti G, Fredriksson L, Herpers B, Meerman J, van de Water B, de Graauw M. TNF-α-mediated NF-κB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochem Pharmacol. 2013;85(2):274–86.CrossRefPubMed Benedetti G, Fredriksson L, Herpers B, Meerman J, van de Water B, de Graauw M. TNF-α-mediated NF-κB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochem Pharmacol. 2013;85(2):274–86.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma
Authors
Xiuru Ma
Xiaoming Li
Xiuying Lu
Lifeng Jia
Hui Li
Qi Song
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3684-8

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine